Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Issue 2 (August 2015)

• Record Type: Journal Article
• Authors: Al-Horani, Rami A.; Gailani, David; Desai, Umesh R.
• Is Part Of: Thrombosis research. Volume 136:Issue 2(2015)
• Page Start: 379
• Page End: 387
• Publication Date: 2015-08
• Subjects: Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2015.04.017
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Recent development of sulfated non-saccharide glycosaminoglycan mimetics, especially sulfated pentagalloyl glucopyranoside (SPGG), as potent inhibitors of factor XIa (FXIa) ( J. Med. Chem. 2013; 56:867-878 and J. Med. Chem. 2014; 57:4805-4818) has led to a strong possibility of developing a new line of factor XIa-based anticoagulants. In fact, SPGG represents the first synthetic, small molecule inhibitor that appears to bind in site remote from the active site. Considering that allosteric inhibition of FXIa is a new mechanism for developing a distinct line of anticoagulants, we have studied SPGG's interaction with FXIa with a goal of evaluating its pre-clinical relevance. Comparative inhibition studies with several glycosaminoglycans revealed the importance of SPGG's non-saccharide backbone. SPGG did not affect the activity of plasma kallikrein, activated protein C and factor XIIIa suggesting that SPGG-based anticoagulation is unlikely to affect other pathways connected with coagulation factors. SPGG's effect on APTT of citrated human plasma was also not dependent on antithrombin or heparin cofactor II. Interestingly, SPGG's anticoagulant potential was diminished by serum albumin as well as factor XI, while it could be reversed by protamine or polybrene, which implies possible avenues for developing antidote strategy. Studies with FXIa mutants indicated that SPGG engages Lys529, Arg530 and Arg532, but not Arg250, Lys252, Lys253 and Lys255. Finally, SPGG competes with unfractionated heparin, but not with polyphosphates and/or glycoprotein Ibα, for binding to FXIa. These studies enhance understanding on the first allosteric inhibitor of FXIa and highlight its value as a promising anticoagulant. Graphical Abstract: Highlights: Sulfated pentagalloyl glucopyranoside (SPGG) inhibits human factor XIa. SPGG is the first synthetic small molecule that allosterically inhibits FXIa. SPGG inhibition of FXIa can be reduced by cationic polymers or serum albumin. SPGG inhibition of FXIa is unaffected by polyphosphates or GPIbα. SPGG binds to Lys529, Arg530 and Arg532 of the catalytic domain of human FXIa.